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Abstract
Background: The Fontan circulation, a result of a palliative procedure in patients with single systemic ventricles,
is defined by chronically elevated pulmonary vascular resistance. When traditional heart failure therapies fail,
pharmacological agents that reduce pulmonary artery pressures may be used. These include endothelial-receptor
antagonists, prostanoids and phosphodiesterase type 5 inhibitors. We report the first use of macitentan, an
endothelin-receptor antagonist, in a patient with a Fontan circulation.
Case presentation: We describe the case of a 50 year old female with tricuspid atresia and transposition of the
great arteries. Following complex surgery as a child, she subsequently underwent a fenestrated modified atrial
pulmonary Fontan operation which was later converted to a total cavopulmonary anastomosis Fontan circulation.
Due to failure of various medications to relieve her worsening symptoms, she was commenced on macitentan in
April 2016. Few months later, she demonstrated a significant symptomatic improvement and associated increase
in her incremental shuttle walking test distance.
Conclusions: Macitentan has slower receptor dissociation kinetics compared to other endothelin-receptor
antagonists, leading to enhanced pharmacological activity with promising effects in patients with pulmonary
arterial hypertension. The patient we report has shown considerable improvement in exercise capacity following
introduction of this medication and thus we suggest further randomised trials to establish the role of different
endothelin-receptor antagonists in the management of the Fontan circulation.
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Background
The Fontan circulation results from a palliative surgical
procedure, which is performed in patients with a func-
tionally single ventricle cardiac anatomy (i.e. univentri-
cular heart). Venous blood is diverted from the vena cava
to the pulmonary artery bypassing the single ventricle.
The success of this operation has resulted in an increasing
population of adults living longer with congenital heart
disease [1].
The Fontan circulation is defined by low cardiac out-
put and elevated central venous pressure. The main
limitation of the Fontan circulation is the absence of a
sub-pulmonary ventricle. Blood flow through the pul-
monary vasculature depends on the gradient between
central venous pressure and ventricular end-diastolic pres-
sure, as well as a low resistance to flow across the pulmon-
ary vascular bed (pulmonary vascular resistance) [1].
It remains to be determined whether late deterioration is
caused by primarily ventricular failure and increasing end
diastolic pressure or if it is due to chronically increased pul-
monary vascular resistance resulting in raised end-diastolic
pressures and therefore increased systemic venous conges-
tion and reduced cardiac output [2]. There is evidence of
pulmonary vascular remodelling in failed Fontan patients
[3], which is difficult to predict by catheter based assess-
ment of pulmonary vascular resistance [4].
Eventually there is a decrease in exercise capacity,
functional status and an increase in heart failure-related
hospital admissions with an increase in mortality [1].
Traditional therapies for heart failure directed at
improving function/decreasing afterload may not be as
relevant in a circulation in which the primary problem
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is filling as opposed to emptying the ventricle. Treat-
ments aiding ventricular filling in the Fontan circula-
tion may be beneficial.
Modulating pulmonary vascular resistance could
improve cardiac output. Reducing pulmonary vascular
resistance improves blood flow across the pulmonary
capillaries, which results in a reduced central venous
pressure and improved cardiac output. Various pharma-
cological agents have shown to reduce pulmonary ar-
tery pressures such as endothelial receptor antagonists
[5] prostanoids [6] and phosphodiesterase type 5 inhibi-
tors [7]. This case report involves the first use of maci-
tentan (an endothelin-receptor antagonist) in a patient
with a Fontan circulation.
Case presentation
We describe the case of a 50 year old Caucasian female
patient who was born with tricuspid atresia and transpos-
ition of the great arteries. At the age of 4, she underwent a
modified Glenn procedure followed by a classical left
Blalock-Taussig shunt at the age of 16. Since then, she has
had two major cardiac operations. In 1990, at the age of
25, she had a fenestrated modified atrial pulmonary
Fontan. Following a very difficult pregnancy 18 years later,
she underwent conversion to a total cavopulmonary
anastomosis Fontan circulation, modified MAZE proced-
ure and implantation of an epicardial defibrillator with
biventricular pacemaker system. Cardiac catheterisation at
that time showed a ventricular end diastolic pressure of
16 mmHg and a Fontan chamber pressure of 18 mmHg,
giving a transpulmonary gradient of 2 mmHg. Her cardiac
medical history was further complicated with arrhythmias
requiring ablation in 1998 and episodes of non-sustained
ventricular tachycardia in 2014.
This lady has been under regular follow-up by our
team since 2008. Various medications have been trialled
over the last 8 years due to her progressive reduction in
exercise capacity and exertional dyspnoea. She had ini-
tially taken part in a trial to test the safety of bosentan
in 2010 [5] and at the time had shown good response to
the drug with improvement in 6-min walk test. Bosentan
was discontinued at the end of the study.
Unfortunately, over the course of the next few years,
she continued to deteriorate with worsening breath-
lessness (NYHA III), four-pillow orthopnoea and par-
oxysmal nocturnal dyspnoea, ventricular function was
preserved. She noticed a significant limitation in everyday
activities, requiring social care input and a mobility
scooter for outdoor travel. Sildenafil was commenced
however this was discontinued shortly after due to symp-
tomatic hypotension.
Cardiac CT scan confirmed non-restrictive Fontan path-
way, and normal ventricular function.
In early 2016, bosentan was re-commenced with good
symptomatic improvement. Unfortunately on this occa-
sion, this was poorly tolerated with significant side effects
(peripheral oedema, pruritus) and thus stopped. On the
basis of her symptomatic improvement with bosentan we
decided to try an alternative endothelin-receptor antagon-
ist, macitentan to alleviate symptoms.
Macitentan (10 mg once daily) was initiated in April
2016. At 5-month review, the patient reported symptom-
atic improvement and this was associated with an increase
in her incremental shuttle walking test distance from
160 m pre-treatment (prior to bosentan administration) to
200 m post-treatment with macitentan. She has not re-
ported any significant side effects. Her echocardiogram
remained unchanged with normal systemic ventricular
internal dimensions and good radial systolic function
(ejection fraction 55–60%).
Discussion and Conclusions
This is the first patient with Fontan circulation that has
been commenced on macitentan. Macitentan belongs to
the family of endothelin-receptor antagonists (ERAs) [8].
Macitentan has significantly slower receptor dissociation
kinetics than other ERAs contributing towards an en-
hanced pharmacological activity compared to the other
ERAs [5]. In the randomised-control SERAPHIN study,
macitentan significantly improved health-related quality
of life in Pulmonary Arterial Hypertension (PAH) pa-
tients compared to placebo, and both 3 mg & 10 mg
doses of macitentan significantly reduced the risk of the
composite endpoint of morbidity and mortality [9].
There is limited published evidence to support the use of
pulmonary vasodilator therapy in Fontan circulation failure.
A recent systematic review identifed improvements in
exercise capacity, exercise haemodynamics and ventricular
performance following the administration of bosentan and
sildenafil in pulmonary hypertension [10]. The TEMPO
study was a randomised, placebo-controlled, double-blind
study assessing the medium-term effect of bosentan on
exercise capacity and functional class together with a safety
assessment in Fontan patients. The results were encour-
aging as there was a significant difference in oxygen con-
sumption, functional class and exercise capacity in the
Bosentan group versus the placebo group with no increase
in side effect profile [11]. Giardini et al. [7] performed a
randomised study assessing the effects of sildenafil on
cardiopulmonary exercise testing in Fontan patients in the
short term; this study demonstrated that sildenafil im-
proved exercise capacity and haemodynamic response to
exercise.
There remain concerns regarding late liver complica-
tions in the Fontan circulation, and ERAs have been re-
ported to cause liver dysfunction in a minority of patients.
In our own safety study [5] and in the TEMPO study [11]
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no liver complications were reported and in our patient
no liver dysfunction has been recorded. All patients on an
ERA are required to have monthly liver function tests
performed.
In this case report, both Bosentan and Sildenafil medica-
tions were tried, however they had to be discontinued due
to intrusive side effects. In view of the promising evidence
of the success of macitentan in PAH, this was considered
as a potential positive treatment in a patient with Fontan
circulation. The patient has shown considerable improve-
ment in exercise capacity following introduction of this
medication and thus we suggest further randomised trials
to establish the role of ERAs in the management of the
Fontan circulation.
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